Brachytherapy

The addition of pembrolizumab to chemoradiotherapy improved survival outcomes for women with high-risk, locally advanced cervical cancer, according to data presented at Society of Gynecologic Oncology Annual Meeting on Women’s Cancer.

Michael J. Zelefsky, MD, has been appointed director of brachytherapy for NYU Langone’s Perlmutter Cancer Center.

Chemoradiotherapy with a contact X-ray brachytherapy boost significantly increased clinical complete response and 3-year organ preservation rates in patients with early cT2-cT3 rectal adenocarcinoma, particularly tumors smaller than 3 cm.

Assessment of sexual function occurred far less often among women undergoing brachytherapy for cervical cancer than men who received the internal radiotherapy for prostate cancer, according to results of a retrospective analysis.

Yes: Brachytherapy for the treatment of intracranial malignancies holds tremendous promise for optimal management of these frequently complex patients.

Although therapeutic advances during the past decade have dramatically improved cancer outcomes overall, the outlook for patients with malignant brain tumors has remained poor.

Two-year results of the MERLOT trial showed no benefit of epimacular brachytherapy as an adjunct to anti-VEGF injections. In fact, the combined therapy group had worse results overall compared with the ranibizumab monotherapy group.

A new guideline issued by the American Society for Radiation Oncology addresses the use of radiation therapy for the treatment of nonmetastatic cervical cancer.

Patient-reported adverse effect profiles 5 years after contemporary treatment for localized prostate cancer could help inform treatment choices for this patient population, according to study results published in JAMA.

Patients treated with iodine-125 brachytherapy for uveal melanoma could have a substantial risk for developing open-angle or neovascular glaucoma.